MK-6482-005

The primary objective of this study is to compare belzutifan to everolimus with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR) and to compare everolimus with respect to overall survival (OS). The hypothesis is that belzutifan is superior to everolimus with respect to PFS and OS

Kurzinformation

männlich weiblich

Urologie Tumorerkrankungen

18 99

Nichts verpassen!

Sie sind an regelmäßigen Informationen über neue Studien der Hochschulmedizin Dresden interessiert? Dann registrieren Sie sich jetzt!